Nasopharyngeal Carcinoma Clinical Trial
Official title:
A Single Center, Open-label, Randomized Controlled Clinical Trial on the Early and Whole Course Nutritional Support by Nutren® Optimum During Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). The most frequently occurred radiation-related side effect is probably the radiation-induced oral mucositis, which affects up to 100% of NPC patients receiving radiation therapy, especially combined with chemotherapy. Significant weight loss caused by Oral mucositis will keep patients in worse nutrition status and then to decline immune function, hematopoietic function and repair function, which will influence the patient's quality of life, reduce the tolerance of treatment, and affect treatment effect. At present, the guidelines at home and abroad more and more emphasize that early nutrition treatment and intervention before systemic malnutrition, also suggest nutrition treatment and intervention at the same time of anti-tumor treatment. First choice of nutritional intervention is oral nutrition supplement. Nutren® Optimum has a higher protein ratio and 50% of the protein sources were lactalbumin and 50% casein. Lactalbumin is a high-quality protein, with the highest nutritional value among a variety of proteins. A cup of 210ml's Nutren® Optimum contains 5g lactalbumin. Nutren® Optimum also contains dietary fiber, vitamin E, monounsaturated fat, L-carnitine, 30 kinds of vitamins and minerals and other nutrients, which can provide a comprehensive and balanced nutrition. This single center, open-label, randomized controlled clinical trial selects Nutren® Optimum as oral nutritional support for interventional group while routine diet guidance for control group, aiming to evaluate the efficacy and safety of early and whole course nutritional support by Nutren® Optimum during intensity modulated radiation therapy for nasopharyngeal carcinoma which can improve patients' nutritional state and quality of life, reduce side effects and improve the tolerability and effectiveness of antitumor treatment.
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). The
most frequently occurred radiation-related side effect is probably the radiation-induced oral
mucositis, which affects up to 100% of NPC patients receiving radiation therapy, especially
combined with chemotherapy.
Oral mucositis is just the most common cause of significant weight loss for patients with
nasopharyngeal carcinoma during treatment. Patients with oral mucositis will have restriction
of normal food, and alternative to semi liquid or liquid diet, resulting in inadequate
nutritional intake, malnutrition, weight loss. Furthermore, worse nutrition status will
decline immune function, hematopoietic function and repair function, which will influence the
patient's quality of life, reduce the tolerance of treatment, and affect treatment effect.
At present, the guidelines at home and abroad more and more emphasize that early nutrition
treatment and intervention before systemic malnutrition, also suggest nutrition treatment and
intervention at the same time of anti-tumor treatment. Therefore, the timing of nutritional
intervention changes from ineffective antitumor therapy as a palliative treatment to the
early start of antitumor therapy. For nasopharyngeal carcinoma, early and whole course
nutritional intervention can prevent and treat malnutrition or cachexia; improve the
treatment tolerance and compliance; control or improve certain adverse reactions of
radiotherapy; improve the quality of life; and then improve the function and curative effect.
First choice of nutritional intervention is oral nutrition supplement. For patients without
gastrointestinal dysfunction, parenteral nutrition is not necessary, even harmful, increasing
the risk of infection.
Nutren® Optimum has a higher protein ratio (P:F:C = 17:35:48), and 50% of the protein sources
were lactalbumin and 50% casein. Lactalbumin is a high-quality protein, which dissolved and
dispersed in the whey protein. Lactalbumin is easy digestion and absorption, with high
bioavailability, and net protein utilization rate (NPU) is higher than that of casein and soy
protein. Lactalbumin is rich in branched chain amino acids, which can be used as energy
material for energy. Lactalbumin has a sulfur-containing amino acid, which can maintain the
level of GSH and be in the role of antioxidation; containing glutamine, which contributes to
muscle glycogen update and improves immune function. In addition, lactalbumin can also
significantly reduce neutrophil apoptosis, enhance neutrophil migration and phagocytosis, and
enhance the immune function. Therefore, lactalbumin has the highest nutritional value among a
variety of proteins, known as protein king. A cup of 210ml's Nutren® Optimum contains 5g
lactalbumin.
Nutren® Optimum contains dietary fiber, which produces short chain fatty acids to promote the
proliferation of intestinal probiotics, and play anti-inflammatory, pro-apoptotic, anti-tumor
effect, and maintain intestinal health. At the same time, vitamin E is specially added in
Nutren® Optimum to protect T lymphocytes, protect red blood cells, anti-oxidation, inhibit
platelet aggregation, enhance immunity, and so on. In addition, 64% fat sources of Nutren®
Optimum are monounsaturated fat, which conducive to the metabolism of glucose and lipid.
Especially added L-carnitine can promote fat oxidation by using better fat for energy,
without reducing water and muscle. Nutren® Optimum provides 30 kinds of vitamins and minerals
and other nutrients, and can provide a comprehensive and balanced nutrition.
This single center, open-label, randomized controlled clinical trial selects Nutren® Optimum
as oral nutritional support for interventional group while routine diet guidance for control
group, aiming to evaluate the efficacy and safety of early and whole course nutritional
support by Nutren® Optimum during intensity modulated radiation therapy for nasopharyngeal
carcinoma, which can improve patients' nutritional state and quality of life, reduce side
effects and improve the tolerability and effectiveness of antitumor treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979961 -
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT06055816 -
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05547971 -
Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
|
||
| Not yet recruiting |
NCT05020925 -
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04547088 -
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04548271 -
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02795169 -
Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02569788 -
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02801487 -
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02237924 -
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02044562 -
Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
|
N/A | |
| Terminated |
NCT01694576 -
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
|
Phase 2 | |
| Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01271439 -
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT00535795 -
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
|
Phase 3 | |
| Completed |
NCT00379262 -
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
|
Phase 3 | |
| Completed |
NCT03398980 -
Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
|
N/A | |
| Completed |
NCT01309633 -
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
|
Phase 2 |